Key Points The tariffs were reinstated by a court, and this has driven up risks once ...

H.C. Wainwright analyst Matthew Hedberg adjusted the price target on Invivyd Inc. (NASDAQ:IVVD) from $10 to $5, while ...

Short interest in Invivyd Inc (NASDAQ:IVVD) increased during the last reporting period, rising from 7.01M to 7.54M. This put 9.5% of the company's publicly available shares short. Short interest ...

Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive ...

Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® ...

WALTHAM, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today commends new U.S. Food and Drug Administration (FDA) leadership on taking important steps to acknowledge and ...

Invivyd (NASDAQ:IVVD – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga ...

Invivyd Inc (IVVD) reports a 15% reduction in operating expenses and explores new viral targets, while navigating sales transitions and regulatory hurdles. WALTHAM, Mass., May 14, 2025 (GLOBE NEWSWIRE ...

Invivyd Inc (NASDAQ:IVVD) has internalized its commercial organization, which is expected to drive broader adoption of PEMGARDA and improve commercial results. The company has secured access to ...

Potential Non-Dilutive Funding: Up to $30 million through a term loan facility with SVB. Invivyd Inc (NASDAQ:IVVD) has internalized its commercial organization, which is expected to drive broader ...